Overview

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Sutro Biopharma, Inc.
Treatments:
Antibodies
Folic Acid Antagonists